AIM ImmunoTech Inc.AIM
Price (close)
$0.19
Market cap
$7.4M
P/E
—
Revenue (TTM)
$95,000
Net income
-$14.3M
Dividend yield
—
1-year total return
-93.2%
Net margin
-15021.1%
Revenue growth
-21.5%
Debt / equity
0.94x
What AIM ImmunoTech Inc. does.
an immuno-pharma company headquartered in Ocala, Florida, and focused on the research and development of therapeutics to treat multiple
types of cancers, viral diseases and immune-deficiency disorders for which there are inadequate or unmet therapies. We have established
a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $163,000 | $135,000 | $141,000 | $202,000 | $170,000 | $88,000 |
| Net income | -$14.4M | -$19.1M | -$19.4M | -$29.0M | -$17.3M | -$14.0M |
| Free cash flow | -$10.4M | -$14.0M | -$16.2M | — | -$14.9M | — |
More on AIM.
- AIM ImmunoTech Inc. summary
- AIM ImmunoTech Inc. financial statements
- AIM ImmunoTech Inc. key metrics
- AIM ImmunoTech Inc. health scores and style box
- AIM ImmunoTech Inc. earnings
- AIM ImmunoTech Inc. dividends
- AIM ImmunoTech Inc. valuation
- AIM ImmunoTech Inc. ownership and insiders
- AIM ImmunoTech Inc. peers
Figures from AIM ImmunoTech Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.